Publications by authors named "Llywelyn Cadman-Davies"
Objective: The objective of this study is to critically assess the diverse indications for HAS administration over the past 8 years at a prominent tertiary care institution in the United Kingdom.
Background: This is timely and relevant, given recent developments in the field. The International Collaborative Transfusion Medicine Group (ICTMG) issued updated guidance on intravenous albumin use in March 2024, reflecting a shift towards more stringent criteria for its application, which necessitates a re-evaluation of current practices.
Article Synopsis
- Pegylated interferons, particularly peginterferon alfa-2a, are commonly used to treat Myeloproliferative Neoplasms (MPN), but a newer drug called ropeginterferon alfa-2b (ropegIFN) has emerged as an option, especially for Polycythaemia Vera (PV).
- RopegIFN received a recommendation from the European Medicine Authority (EMA) and FDA approval in November 2021 after positive results from Phase III trials.
- The study highlights the safety and tolerability of ropegIFN in MPN patients, confirming its efficacy in treating PV and its potential use during pregnancy.